頁籤選單縮合
題名 | 轉移性黑色素瘤的治療新進展=Novel Approaches in the Management of Advanced Melanoma |
---|---|
作者姓名(中文) | 許育瑋; | 書刊名 | 藥學雜誌 |
卷期 | 33:3=132 2017.09[民106.09] |
頁次 | 頁17-23 |
分類號 | 415.691 |
關鍵詞 | 轉移性黑色素瘤; 分子標靶治療; 免疫治療; BRAF; CTLA-4; PD-1; |
語文 | 中文(Chinese) |
中文摘要 | 黑色素瘤約只佔皮膚癌的5%左右,但卻是皮膚癌症中死亡率最高的癌別。當黑 色素瘤轉移後的存活率會大幅降低至不到2成,是目前治療上需要面對的挑戰。近年 來對黑色素瘤免疫生物學的了解,加速了新一代藥物的興起。這些新的藥物主要作用 在黑色素細胞中的 MAPK (mitogen activated protein kinase) 路徑,以及作用在T細胞上 可以活化T細胞免疫能力的蛋白質;這些藥物在反應率及整體存活率上得到了較佳的 改善,可說是開啟了轉移性黑色素瘤治療的新頁。 |
英文摘要 | Advanced melanoma account for only 2-5% of dermatologic cancers, but it’s the major cause of death in skin cancer. The survival rate radically declines to less than 20% in advanced or metastatic cases, and it’s always been a great challenge to clinicians. The findings in the immunobiology of melanoma in the last few years facilitate a rapid emergence of novel therapies. These new drugs mainly act on MAPK (mitogen activated protein kinase) pathway in melanoma cells, and activate T cell immunocompetent proteins in T cells. Those provided response and survival improvement, and therefore entered a new era in the management of advanced melanoma. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。